Cross-species recognition of bat coronavirus RsYN04 and cross-reaction of SARS-CoV-2 antibodies against the virus  

作　　者：Runchu Zhao Sheng Niu Pu Han Yue Gao Dezhi Liu Chunliang Luo Honghui Liu Bo Liu Yanli Xu Jianxun Qi Zhihai Chen Weifeng Shi Lili Wu George F.Gao Qihui Wang 

机构地区：[1]Institute of Physical Science and Information,Anhui University,Hefei,Anhui 230039,China [2]CAS Key Laboratory of Pathogen Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China [3]College of Veterinary Medicine,Shanxi Agricultural University,Jinzhong,Shanxi 030801,China [4]School of Life Sciences,Hebei University,Baoding,Hebei 071002,China [5]Center of Infectious Disease,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China [6]Key Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong,Shandong First Medical University&Shandong Academy of Medical Sciences,Taian,Shandong 271000,China [7]University of Chinese Academy of Sciences,Beijing 100049,China

出　　处：《Zoological Research》2023年第6期1015-1025,共11页动物学研究（英文）

基　　金：supported by the National Key R&D Program of China (2022YFC2303403);National Natural Science Foundation of China (82225021);supported by the Chinese Academy of Sciences (YSBR-010 and Y2022037)。

摘　　要：Following the outbreak of coronavirus disease 2019(COVID-19),several severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)-related coronaviruses have been discovered.Previous research has identified a novel lineage of SARS-CoV-2-related CoVs in bats,including RsYN04,which recognizes human angiotensin-converting enzyme 2(ACE2)and thus poses a potential threat to humans.Here,we screened the binding of the RsYN04receptor-binding domain(RBD)to ACE2 orthologs from 52animal species and found that the virus showed a narrower ACE2-binding spectrum than SARS-CoV-2.However,the presence of the T484W mutation in the RsYN04 RBD broadened its range.We also evaluated 44 SARS-CoV-2antibodies targeting seven epitope communities in the SARS-CoV-2 RBD,together with serum obtained from COVID-19 convalescents and vaccinees,to determine their cross-reaction against RsYN04.Results showed that no antibodies,except for the RBD-6 and RBD-7 classes,bound to the RsYN04 RBD,indicating substantial immune differences from SARS-CoV-2.Furthermore,the structure of the RsYN04 RBD in complex with cross-reactive antibody S43 in RBD-7 revealed a potently broad epitope for the development of therapeutics and vaccines.Our findings suggest RsYN04 and other viruses belonging to the same clade have the potential to infect several species,including humans,highlighting the necessity for viral surveillance and development of broad anticoronavirus countermeasures.

关 键 词：SARS-CoV-2-related coronavirus RsYN04 ACE2 Antibody Structure 

分 类 号：Q939.4[生物学—微生物学]